In this editorial I comment on the article,published in the current issue of the World Journal of Clinical Oncology.Primary central nervous system lymphoma(PCNSL)is a disease of elderly and immunocompromised patients....In this editorial I comment on the article,published in the current issue of the World Journal of Clinical Oncology.Primary central nervous system lymphoma(PCNSL)is a disease of elderly and immunocompromised patients.The authors reported clinical results of 19 patients with PCNSL treated with zanubrutinib/high dose methotrexate(HD-MTX)until disease progression.They demonstrated that the combination of zanubrutinib with HD-MTX led to a marked clinical response and tolerability among these patients.They also observed that cerebrospinal fluid liquid biopsy to detect circulating tumor DNA may be a good option for evaluating treatment response and tumor burden in patients with PCNSL.PCNSL is a challenging disease for treatment as these patients present with different neurological states and comorbidities.Treatment has evolved over the years from whole brain radiotherapy to HD-MTX followed by autologous stem cell transplant.Gradually,treatment of patients with PCNSL is going to become individualized.展开更多
1.INTRODUCTION Vitreoretinal lymphoma(VRL)is a rare subtype of central nervous system lymphoma(CNSL)that predominantly comprises B-cell lymphomas.Because of its clinical resemblance to uveitis and transient response t...1.INTRODUCTION Vitreoretinal lymphoma(VRL)is a rare subtype of central nervous system lymphoma(CNSL)that predominantly comprises B-cell lymphomas.Because of its clinical resemblance to uveitis and transient response to glucocorticoid therapy,the diagnosis of VRL is often delayed.1 Although initial manifestations appear indolent,the disease can lead to irreversible vision loss or central nervous system(CNS)relapse,resulting in a poor prognosis.2 Based on the site of initial malignant lymphocyte infiltration,primary VRL(PVRL)originates in the vitreous or retina without CNS or systemic involvement,whereas secondary VRL(SVRL)arises from CNSL or systemic lymphoma.展开更多
文摘In this editorial I comment on the article,published in the current issue of the World Journal of Clinical Oncology.Primary central nervous system lymphoma(PCNSL)is a disease of elderly and immunocompromised patients.The authors reported clinical results of 19 patients with PCNSL treated with zanubrutinib/high dose methotrexate(HD-MTX)until disease progression.They demonstrated that the combination of zanubrutinib with HD-MTX led to a marked clinical response and tolerability among these patients.They also observed that cerebrospinal fluid liquid biopsy to detect circulating tumor DNA may be a good option for evaluating treatment response and tumor burden in patients with PCNSL.PCNSL is a challenging disease for treatment as these patients present with different neurological states and comorbidities.Treatment has evolved over the years from whole brain radiotherapy to HD-MTX followed by autologous stem cell transplant.Gradually,treatment of patients with PCNSL is going to become individualized.
基金Funding received from Noncommunicable Chronic Diseases-National Science and Technology Major Project(2025ZD0544300).
文摘1.INTRODUCTION Vitreoretinal lymphoma(VRL)is a rare subtype of central nervous system lymphoma(CNSL)that predominantly comprises B-cell lymphomas.Because of its clinical resemblance to uveitis and transient response to glucocorticoid therapy,the diagnosis of VRL is often delayed.1 Although initial manifestations appear indolent,the disease can lead to irreversible vision loss or central nervous system(CNS)relapse,resulting in a poor prognosis.2 Based on the site of initial malignant lymphocyte infiltration,primary VRL(PVRL)originates in the vitreous or retina without CNS or systemic involvement,whereas secondary VRL(SVRL)arises from CNSL or systemic lymphoma.
